Diligence memo · auto-generated · as of July 2, 2026
Diadexus Inc
Diadexus Inc looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Diadexus Inc operates in Biotechnology, based in South San Francisco.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Diadexus Inc has raised $4.5M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $4.5M on 2010-05-28.
Most recent recorded round closed around 2010-05-28.
Valuation (modeled)modeled
Provath models Diadexus Inc at approximately $163M (range $4.9M–$885M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.81× the median modeled value of Series A Biotechnology companies in 2010–2012 (92 peers) — value vs value, same stage and era. Within the normal band (81% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 16.1 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 41% of Biotechnology peers (4293 compared).
Modeled value ranks above 68% of those peers.
Closest niche peers: Tobira Therapeutics, Inc., Neoprobe Corp, Akebia Therapeutics, Inc., Adimab, LLC, Elevation Pharmaceuticals Inc.
Peoplefiled
8 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.